




# Understanding KRAS G12C in Non-Small Cell Lung Cancer (NSCLC)

## THE IMPACT OF LUNG CANCER



**2<sup>nd</sup>** most common cancer in the U.S.<sup>1</sup>




**Leading cause** of cancer death for men and women, making up more than **25% of cancer deaths.**<sup>1</sup>

## ABOUT LUNG CANCER



A disease in which **cancerous cells form in the tissues of the lung.**<sup>2</sup>



**NSCLC is the most common type of lung cancer,** accounting for **~85%** of lung cancers.<sup>1</sup>



Despite recent significant advances in the treatment of advanced lung cancer, there remains a **high unmet need** for patients and **outcomes remain poor.**<sup>4</sup>



**More than half of patients** have advanced disease at diagnosis.<sup>3</sup>



Metastatic or advanced lung cancer is **lung cancer that has spread.**<sup>3</sup>



The **stage** of a patient's lung cancer at diagnosis is based upon how much cancer is present and the extent of its spread within the body, which **can impact the prognosis.**<sup>4</sup>

## KRAS G12C – A NEWLY ACTIONABLE BIOMARKER

**~50%**

of NSCLC patients have an oncogene that **initiates cancer** and **contributes to its growth.**<sup>5</sup>



**KRAS** is one of the most prevalent driver mutation in NSCLC,<sup>6</sup> and nearly **1/2 of all KRAS mutations in the US are KRAS G12C.**<sup>7,8</sup>



**KRAS G12C** occurs in **~13%, or 1 in 8,** of patients with NSCLC in the U.S.<sup>9</sup>

## BIOMARKER TESTING IS CRITICAL AT DIAGNOSIS



**Biomarker testing** allows for the detection of driver mutations that initiate and support the growth of cancer.<sup>10</sup>



Comprehensive biomarker testing at diagnosis is critical because it can help doctors and patients develop a **targeted and personalized treatment plan** to help improve patient outcomes.<sup>10,11</sup>



Professional medical organizations **recommend comprehensive testing for actionable and emerging biomarkers at the time of diagnosis** for patients with advanced NSCLC.<sup>12-14</sup>

Treatment with targeted therapy is associated with **improved outcomes** for patients with a mutational driver identified by biomarker testing\*<sup>10</sup>

## NSCLC TREATMENT OPTIONS

Depending on stage at diagnosis and a patient's biomarker status, treatment options may include:<sup>15</sup>



**chemotherapy**



**immunotherapy**



**radiation**



**surgery**



**targeted therapies**

**To learn more visit [Amgen.com/knowkras](https://www.amgen.com/knowkras)**

1. ACS. About Lung Cancer – Key Statistics. Available at: <https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html>. Accessed 4/25/2021. 2. ACS. About Lung Cancer – What is Lung Cancer? Available at: <https://www.cancer.org/cancer/lung-cancer/about/what-is.html>. Accessed 4/25/2021. 3. Siegel R, et al. Cancer Statistics, 2021. *CA Cancer J Clin*. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. 4. ACS. Early Detection, Diagnosis, and Staging – Lung Cancer Survival Rates. Available at: <https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html>. Accessed 4/25/2021. 5. Baumgart M, Am J Hematol Oncol. 2015;11:10-13. 6. Pakkala S, et al. *JCI Insight*. 2018:e120858. 7. Arbour KC, et al. *Clin Cancer Res*. 2018;24:334-340. 8. Cox AD, et al. *Nat Rev Drug Discov*. 2014;13:828-851. 9. Amgen Data on File: Analysis of AACR Genie v8, 7-A-Table. 10. Kris MG, et al. *JAMA*. 2014;311:1998-2006. 11. Barlesi F, et al. *Lancet*. 2016;387:1415-1426. 12. Gregg JP, et al. *Transl Lung Cancer Res*. 2019;8:286-301. 13. Pennell NA, et al. *Am Soc Clin Oncol Educ Book*. 2019;39:531-542. 14. Gierman HJ, et al. *J Clin Oncol*. 2019;37(15\_Suppl):Abstract 1585. 15. ACS. Treating Non-Small Cell Lung Cancer. Available at: <https://www.cancer.org/cancer/lung-cancer/treating-non-small-cell.html>. Accessed 4/25/21.

\*Median overall survival (mOS) of 3.5 months in patients receiving targeted therapy enabled by biomarker testing compared to 2.4 months mOS in patients with a driver mutation not receiving targeted therapy.<sup>10</sup>